Thomas Daugbjerg Madsen

Thomas Daugbjerg Madsen

Auto-generated profile, based on publicly available information

Thomas Daugbjerg Madsen

Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Immunity
Verified
Journal Article
Closed access
Avery Posey, Jr.Avery Posey, Jr.
Avery Posey, Jr.
RSRobert D. Schwab
Robert D. Schwab
ABAlina C. Boesteanu
Alina C. Boesteanu
CSCatharina Steentoft
Catharina Steentoft
UMUlla Mandel
Ulla Mandel
CJCarl H. June
Carl H. June

23 February 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
SKSarah L. King
Sarah L. King
HJHiren J. Joshi
Hiren J. Joshi
KSKatrine T. Schjoldager
Katrine T. Schjoldager
AHAdnan Halim
Adnan Halim
TMThomas D. Madsen
Thomas D. Madsen
HWHans Wandall
Hans Wandall
Key Points: Human platelets, endothelial cells, and plasma proteins are extensively O-glycosylated, with >1123 O-glycosites identified in this study. O-glycosites can be classified into functional subgroups; one important function includes the protection from proteolytic processing.

25 August 2014 in Glycobiology
Verified
Journal Article
Open access
PDF file
YKYun Kong
Yun Kong
HJHiren J Joshi
Hiren J Joshi
KSKatrine Ter-Borch Gram Schjoldager
Katrine Ter-Borch Gram Schjoldager
TMThomas Daugbjerg Madsen
Thomas Daugbjerg Madsen
TGThomas A Gerken
Thomas A Gerken
HCHenrik Clausen
Henrik Clausen
N-acetylgalactosaminyltransferase (GalNAc)-type (mucin-type) O-glycosylation is an abundant and highly diverse modification of proteins. This type of O-glycosylation is initiated in the Golgi by a large family of up to 20 homologous polypeptide GalNAc-T isoenzymes that transfer GalNAc to Ser, Thr and possibly Tyr residues. These GalNAc residues are then further elongated by a large set of glycosyltransferases to build a variety of complex O-glycan structures. What determines O-glycan site occupancy is still poorly understood, although it is clear that the substrate specificities of individual isoenzymes and the repertoire of GalNAc-Ts in cells are key parameters. The GalNAc-T isoenzymes are differentially expressed in cells and tissues in principle allowing cells to produce unique O-glycoproteomes dependent on the specific subset of isoforms present. In vitro analysis of acceptor peptide substrate specificities using recombinant expressed GalNAc-Ts has been the method of choice for probing activities of individual isoforms, but these studies have been hampered by biological validation of actual O-glycosylation sites in proteins and number of substrate testable. Here, we present a systematic analysis of the activity of 10 human GalNAc-T isoenzymes with 195 peptide substrates covering known O-glycosylation sites and provide a comprehensive dataset for evaluating isoform-specific contributions to the O-glycoproteome.

20 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
TMThomas D. Madsen
Thomas D. Madsen
LHLasse H. Hansen
Lasse H. Hansen
JHJohn Hintze
John Hintze
ZYZilu Ye
Zilu Ye
SJShifa Jebari
Shifa Jebari
KSKatrine T. Schjoldager
Katrine T. Schjoldager
Peptide hormones and neuropeptides encompass a large class of bioactive peptides that regulate physiological processes like anxiety, blood glucose, appetite, inflammation and blood pressure. Here, we execute a focused discovery strategy to provide an extensive map of O-glycans on peptide hormones. We find that almost one third of the 279 classified peptide hormones carry O-glycans. Many of the identified O-glycosites are conserved and are predicted to serve roles in proprotein processing, receptor interaction, biodistribution and biostability. We demonstrate that O-glycans positioned within the receptor binding motifs of members of the neuropeptide Y and glucagon families modulate receptor activation properties and substantially extend peptide half-lives. Our study highlights the importance of O-glycosylation in the biology of peptide hormones, and our map of O-glycosites in this large class of biomolecules serves as a discovery platform for an important class of molecules with potential opportunities for drug designs.

1 June 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
NPNis Borbye Pedersen
Nis Borbye Pedersen
SWShengjun Wang
Shengjun Wang
YNYoshiki Narimatsu
Yoshiki Narimatsu
ZYZhang Yang
Zhang Yang
AHAdnan Halim
Adnan Halim
HCHenrik Clausen
Henrik Clausen
The low density lipoprotein receptor (LDLR) is crucial for cholesterol homeostasis and deficiency in LDLR functions cause hypercholesterolemia. LDLR is a type I transmembrane protein that requires O-glycosylation for stable expression at the cell surface. It has previously been suggested that LDLR O-glycosylation is found N-terminal to the juxtamembrane region. Recently we identified O-glycosylation sites in the linker regions between the characteristic LDLR class A repeats in several LDLR-related receptors using the “SimpleCell” O-glycoproteome shotgun strategy. Herein, we have systematically characterized O-glycosylation sites on recombinant LDLR shed from HEK293 SimpleCells and CHO wild-type cells. We find that the short linker regions between LDLR class A repeats contain an evolutionarily conserved O-glycosylation site at position −1 of the first cysteine residue of most repeats, which in wild-type CHO cells is glycosylated with the typical sialylated core 1 structure. The glycosites in linker regions of LDLR class A repeats are conserved in LDLR from man to Xenopus and found in other homologous receptors. O-Glycosylation is controlled by a large family of polypeptide GalNAc transferases. Probing into which isoform(s) contributed to glycosylation of the linker regions of the LDLR class A repeats by in vitro enzyme assays suggested a major role of GalNAc-T11. This was supported by expression of LDLR in HEK293 cells, where knock-out of the GalNAc-T11 isoform resulted in the loss of glycosylation of three of four linker regions.

1 December 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JHJohn Hintze
John Hintze
ZYZilu Ye
Zilu Ye
YNYoshiki Narimatsu
Yoshiki Narimatsu
TMThomas Daugbjerg Madsen
Thomas Daugbjerg Madsen
HJHiren J. Joshi
Hiren J. Joshi
KSKatrine T. Schjoldager
Katrine T. Schjoldager
The GalNAc-type O-glycoproteome is orchestrated by a large family of polypeptide GalNAc-transferase isoenzymes (GalNAc-Ts) with partially overlapping contributions to the O-glycoproteome besides distinct nonredundant functions. Increasing evidence indicates that individual GalNAc-Ts co-regulate and fine-tune specific protein functions in health and disease, and deficiencies in individual GALNT genes underlie congenital diseases with distinct phenotypes. Studies of GalNAc-T specificities have mainly been performed with in vitro enzyme assays using short peptide substrates, but recently quantitative differential O-glycoproteomics of isogenic cells with and without GALNT genes has enabled a more unbiased exploration of the nonredundant contributions of individual GalNAc-Ts. Both approaches suggest that fairly small subsets of O-glycosites are nonredundantly regulated by specific GalNAc-Ts, but how these isoenzymes orchestrate regulation among competing redundant substrates is unclear. To explore this, here we developed isogenic cell model systems with Tet-On inducible expression of two GalNAc-T genes, GALNT2 and GALNT11, in a knockout background in HEK293 cells. Using quantitative O-glycoproteomics with tandem-mass-tag (TMT) labeling, we found that isoform-specific glycosites are glycosylated in a dose-dependent manner and that induction of GalNAc-T2 or -T11 produces discrete glycosylation effects without affecting the major part of the O-glycoproteome. These results support previous findings indicating that individual GalNAc-T isoenzymes can serve in fine-tuned regulation of distinct protein functions.